<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2015072123278N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-06-01</date_registration>
      <primary_sponsor>School of Dentistry, Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The efficacy of articaine in mental injection</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of anesthetic efficacy of articaine as a primary injection between infiltration in the incisive/mental nerve region and inferior alveolar nerve block to treat mandibular premolar teeth with irreversible pulpitis: A, randomized, controlled, parallel, double blind study.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-08-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/19880</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Permuted block randomization using sealed enveloped.</study_design>
      <phase>3</phase>
      <hc_freetext>Local anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: IMNI: incisive/mental nerve infiltration&#13;
Injection will be performed with 1.8 ml of articaine 4%with 1:100,000 epinephrine (Articadent; Dentsply Pharmaceutical, York, PA, USA) between the two mandibular premolars teeth, if the second premolar is missing the injection will be distal to the first premolar apex and if the first premolar was missing the injection will be at the apex of the second premolar. After the anesthesia has been confirmed with EPT, the regular root canal treatment will be initiated. If moderate or severe pain on the basis of the values of The Heft-Parker visual analogue scale (HP-VAS) is anticipated the patient will be injected with another cartridge of 4% articaine with 1:100,000 epinephrine (Articadent; Dentsply Pharmaceutical, York, PA, USA) by the inferior alveolar block technique. Intervention 2: Control group: Inferior alveolar nerve block (IANB).&#13;
After isolation of the teeth with cotton rolls and drying them with gauze, fluoride gel or tooth paste will be applied to the probe tip of electric pulp tester and will be placed midway between the gingival margin and the occlusal edge of the tooth that is being tested (according to the manufacturer’s guidelines). &#13;
Injection will be performed with 1.8 ml of 4% articaine with 1:100,000 epinephrine (Articadent; Dentsply Pharmaceutical, York, PA, USA) according to malamed technique.   After the anesthesia has been confirmed with EPT, the regular root canal treatment will be initiated. If moderate or severe pain on the basis of the values of The Heft-Parker visual analogue scale (HP-VAS) is anticipated the patient will be injected with another cartridge of the same solution injection to the mental foramen region.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Sholeh Ghabraei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Endodontics, School of Dentistry, Kargar St, Enghelab Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8835 1173</telephone>
        <email>sholhghabraei@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Sholeh Ghabraei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Endodontics, School of Dentistry, Kargar St, Enghelab Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8835 1173</telephone>
        <email>sholhghabraei@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:&#13;
Healthy patients who seek treatment for mandibular premolar teeth diagnosed with irreversible pulpitis; patients who accept to sign the informed consent&#13;
Exclusion criteria: &#13;
Hematological and clotting disorders; neurological disorders; allergies to local; anesthetic drugs or sulfites; pregnancy at the time of the study; Younger than 18 year older than 65 year; patients with a history of significant medical conditions (American Society of Anesthesiologists class II or higher); clinically observed lesions or swellings at the injection site</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y48.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Local anaesthetics</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: IMNI: incisive/mental nerve infiltration&#13;
Injection will be performed with 1.8 ml of articaine 4%with 1:100,000 epinephrine (Articadent; Dentsply Pharmaceutical, York, PA, USA) between the two mandibular premolars teeth, if the second premolar is missing the injection will be distal to the first premolar apex and if the first premolar was missing the injection will be at the apex of the second premolar. After the anesthesia has been confirmed with EPT, the regular root canal treatment will be initiated. If moderate or severe pain on the basis of the values of The Heft-Parker visual analogue scale (HP-VAS) is anticipated the patient will be injected with another cartridge of 4% articaine with 1:100,000 epinephrine (Articadent; Dentsply Pharmaceutical, York, PA, USA) by the inferior alveolar block technique.</i_keyword>
      <i_keyword>Control group: Inferior alveolar nerve block (IANB).&#13;
After isolation of the teeth with cotton rolls and drying them with gauze, fluoride gel or tooth paste will be applied to the probe tip of electric pulp tester and will be placed midway between the gingival margin and the occlusal edge of the tooth that is being tested (according to the manufacturer’s guidelines). &#13;
Injection will be performed with 1.8 ml of 4% articaine with 1:100,000 epinephrine (Articadent; Dentsply Pharmaceutical, York, PA, USA) according to malamed technique.   After the anesthesia has been confirmed with EPT, the regular root canal treatment will be initiated. If moderate or severe pain on the basis of the values of The Heft-Parker visual analogue scale (HP-VAS) is anticipated the patient will be injected with another cartridge of the same solution injection to the mental foramen region.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anesthesia. Timepoint: during the root canal treatment procedure. Method of measurement: by VAS(visual analogue scale) and EPT(electric pulp tester).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The onst of the anesthesia. Timepoint: before starting the root canal treatment. Method of measurement: by EPT (electric pulp tester).</sec_outcome>
      <sec_outcome>The duration of anesthesia. Timepoint: time  from the confirmation of anesthesia until the anesthesia subsided or the patient start to have pain again. Method of measurement: electric pulp tester and visual analogue scale.</sec_outcome>
      <sec_outcome>Pain. Timepoint: from injection through out the treatment and one week after the treatment. Method of measurement: visual analogue scale (VAS).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>School of Dentistry, Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-02-08</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Tehran, District 6, Pour Sina St Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
